|Target||Clostridium difficile toxin A|
|Chemical and physical data|
|Molar mass||145.9 kg/mol|
This drug, along with bezlotoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School. The project was then licensed to Merck & Co., Inc. for further development and commercialization.
A study compared it with bezlotoxumab (that targets CD toxin-B) and found Actoxumab less effective.
- "Statement On A Nonproprietary Name Adopted By The USAN Council - Actoxumab" (PDF). American Medical Association.
- Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Leney M, Sloan S, Hay CA, Ambrosino DM (January 2010). "Treatment with monoclonal antibodies against Clostridium difficile toxins". N. Engl. J. Med. 362 (3): 197–205. PMID 20089970. doi:10.1056/NEJMoa0907635.
- "Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection". Press Release. Merck Sharp & Dohme Corp.
- New treatment for C.diff infections reduces recurrences by 40%, study finds
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|